Gila Therapeutics is a pioneering brand in the field of obesity and cardiometabolic disorder treatment. As a clinical stage biotech company, Gila Therapeutics leverages a highly-targeted neural signaling system to develop innovative therapeutic solutions. Their approach involves topical/lingual delivery, activating satiety centers in the brain without any systemic exposure.

This breakthrough method avoids the risks associated with systemically delivered therapeutics. Gila's flagship program, Topical Lingual PYY, has already completed a successful Phase I trial with zero treatment-related adverse events or serious adverse events. Furthermore, Gila is actively developing multiple topical lingual hormone targets such as GLP-1, amylin, and leptin.

Headquartered in Boston, MA, Gila Therapeutics boasts a highly experienced team of leaders with extensive expertise in fundraising, clinical trials, and metabolic diseases. With their innovative approach to obesity and metabolic disorders, Gila Therapeutics is revolutionizing the field of therapeutic platforms